Menu
Annual · values20252024202320222021202020192018201720162015
Operating Cash Flow-33.12 M USD-33.97 M USD-25.34 M USD-29.20 M USD-56.37 M USD-137.08 M USD-65.10 M USD-52.73 M USD-28.25 M USD-2.29 M USD-4.18 M USD
Depreciation & Amortization23000 USD4000 USD0 USD72000 USD109000 USD341000 USD350000 USD319000 USD
Stock-Based Compensation2.31 M USD3.30 M USD3.31 M USD4.30 M USD8.08 M USD18.10 M USD6.70 M USD3.64 M USD1.45 M USD573000 USD65000 USD
Capital Expenditures0 USD117000 USD0 USD0 USD113000 USD11000 USD140000 USD27000 USD31000 USD0 USD
Cash Flow from Investing37.37 M USD23.36 M USD-57.35 M USD15.67 M USD1.03 M USD89.11 M USD41.37 M USD-33.88 M USD-15.06 M USD-37.49 M USD0 USD
Cash Flow from Financing-143000 USD-141000 USD82.39 M USD1.65 M USD39.78 M USD61.81 M USD4.99 M USD125.91 M USD49.49 M USD0 USD47.72 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-33.12 M USD-34.09 M USD-25.34 M USD-56.37 M USD-137.19 M USD-65.11 M USD-52.87 M USD-28.27 M USD-2.32 M USD-4.18 M USD

Vyne Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative dermatology solutions. Primarily focused on the treatment of skin diseases, Vyne Therapeutics leverages its proprietary technologies to address conditions such as acne and rosacea. The company's commitment to advancing dermatological research is evident in its pipeline of therapeutic products that aim to enhance the care and management of skin conditions. By working closely with healthcare professionals and leveraging partnerships within the pharmaceutical industry, Vyne Therapeutics strives to deliver effective treatment options that improve patient outcomes. As an active participant in the biopharmaceutical market, Vyne Therapeutics plays a critical role in advancing dermatological therapies, contributing to the broader medical and healthcare sectors by providing solutions that benefit consumers and practitioners alike.